News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
News Adaptimmune progresses T-cell therapy trial Biotech says "robust" clinical response in early stage trial.
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News Akebia joins GSK in US market for oral CKD anaemia drugs The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.